European Medicines Agency’s workshop on nanomedicines

  • Email
  • Help

Details

TitleEuropean Medicines Agency’s workshop on nanomedicines
Date02/09/2010 - 03/09/2010
LocationLondon
SummaryOn 2-3 September 2010, EMA hosted the first international scientific workshop on nanomedicines. Some 200 European and international participants from 27 countries including Australia, Canada, India, Japan and the United States discussed benefits and challenges arising from the application of nanotechnologies to medicines. Participants included representatives from patients’ organisations, health care professionals’ organisations, academia, regulatory authorities and pharmaceutical industry.

All documents

Name Language First published Last updated
Summary report - Workshop on nanomedicines: 2-3 September 2010 (English only) 2010-10-22  
Agenda - Workshop on nanomedicines: 2-3 September 2010 (English only) 2010-03-15 2010-09-09
Presentation - Workshop on nanomedicines - Introduction, Patrick le Courtois, EMA (English only) 2010-09-09  
Presentation - Keynote lecture - Key ongoing applications in nanosciences and how they apply to pharmaceuticals, Rutledge Ellis-Behnke, MIT (English only) 2010-09-09  
Presentation - Engineering nanoparticles for biomedical applications, Mamoun Muhammed, Royal Institute of Technology, Stockholm (English only) 2010-09-09  
Presentation - Special aspects of nanomedicines: development, manufacturing and characterisation, Simon Holland, GlaxoSmithKline (English only) 2010-09-09  
Presentation - Special aspects of nanomedicines: Viewpoint from the industry, Jan Möschwitzer, Abbott Healthcare Products B.V. (English only) 2010-09-09  
Presentation - Immunology and immunotoxicity of nanomedicines, Jacques Descotes, Lyon University Hospitals, France (English only) 2010-09-09  
Presentation - Nanotechnology - What about safety? How do we determine risk? Wim H de Jong, National Institute for Public Health and the Environment, Bilthoven (English only) 2010-09-09  
Presentation - Nanomedicines interaction with biological systems, Kenneth Dawson, University College of Dublin (English only) 2010-09-09  
Presentation - Nanomedicines on the market and in clinical development - Introduction, Eric Abadie, CHMP chair (English only) 2010-09-09  
Presentation - Liposomal nanomedicines and innovative formulations, Daan Crommelin, Utrecht University (English only) 2010-09-09  
Presentation - Polymer conjugates, Ruth Duncan, Cardiff University (English only) 2010-09-09  
Presentation - Nanoparticles, Rogério Gaspar, University of Lisbon (English only) 2010-09-09  
Presentation - Novel and innovative nanotechnology-based delivery systems, Alexander Kabanov, University of Nebraska Medical Center (English only) 2010-09-09  
Presentation - Nanosystems in regenerative medicine, Jöns Hilborn, Uppsala University (English only) 2010-09-09  
Presentation - Theranostics nanoparticles, Peter Dobson, Oxford University (English only) 2010-09-09  
Presentation - Safety specification - Identification and methodologies, Annalisa Rubino, EMA (English only) 2010-09-09  
Presentation - Pharmacovigilance and risk minimisation plans, Jan Petracek, PharmInvent (English only) 2010-09-09  
Presentation - Specific methodological issues and implications for risk assessment, Silvia Berkner, German Federal Environmental Agency (English only) 2010-09-09  
Presentation - Nanomedicines - Current initiatives in the US, Carlos Peña, FDA (English only) 2010-09-09  
Presentation - Nanomedicines - Current initiatives in Japan, Kumiko Sakai-Kato, Toru Kawanishi, National Institute of Health Sciences/MHLW (English only) 2010-09-09  
Presentation - Nanomedicines - Current initiatives in Canada, Duc Vu, Health Canada (English only) 2010-09-09  
Presentation - Way forward, Marisa Papaluca, EMA (English only) 2010-09-09  

Media Videos


Related information